suramin has been researched along with Complication, Postoperative in 2 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This experience suggests the avoidance of elective procedures during the first month after suramin therapy and a heightened awareness of the potential for bleeding and wound healing problems in patients receiving suramin who do require an emergent procedure." | 7.69 | Postoperative complications in patients receiving suramin therapy. ( Cole, DJ; Cooper, MR; Danforth, DN; Ettinghausen, SE; Linehan, MW; Myers, CW; Pass, HI; Sindelar, WF, 1994) |
| " To determine whether suramin, an antagonist of TGF-β, could aid in the prevention of fibrosis, we injected it into the anterior tibialis muscle [12 rabbits received low-dose suramin (50 mg), 12 received high-dose suramin (100 mg), and 12 received sham injections]." | 3.77 | Distraction osteogenesis-induced muscle fibrosis may not be associated with TGF-β1. ( Koplin, SA; McCarthy, J; Mitchell, J; Noonan, KJ; Olabisi, R; Salamat, S; Su, L; Torrealba, J, 2011) |
| "This experience suggests the avoidance of elective procedures during the first month after suramin therapy and a heightened awareness of the potential for bleeding and wound healing problems in patients receiving suramin who do require an emergent procedure." | 3.69 | Postoperative complications in patients receiving suramin therapy. ( Cole, DJ; Cooper, MR; Danforth, DN; Ettinghausen, SE; Linehan, MW; Myers, CW; Pass, HI; Sindelar, WF, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koplin, SA | 1 |
| Su, L | 1 |
| Salamat, S | 1 |
| Torrealba, J | 1 |
| McCarthy, J | 1 |
| Mitchell, J | 1 |
| Olabisi, R | 1 |
| Noonan, KJ | 1 |
| Cole, DJ | 1 |
| Ettinghausen, SE | 1 |
| Pass, HI | 1 |
| Danforth, DN | 1 |
| Linehan, MW | 1 |
| Myers, CW | 1 |
| Cooper, MR | 1 |
| Sindelar, WF | 1 |
2 other studies available for suramin and Complication, Postoperative
| Article | Year |
|---|---|
Distraction osteogenesis-induced muscle fibrosis may not be associated with TGF-β1.
Topics: Animals; Ankle Joint; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Immunohist | 2011 |
Postoperative complications in patients receiving suramin therapy.
Topics: Adult; Aged; Aged, 80 and over; Drug Evaluation; Female; Hemorrhage; Humans; Infusions, Intravenous; | 1994 |